Table 4.
Multivariate Cox regression analysis including established prognostic parameters and the TFAP2D expression in all prostate cancers and in the subsets of ERG negative and ERG positive prostate cancers
| Tumor subset | Scenario | n | p-value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| preoperative PSA-Level | pT Stage | cT Stage | Gleason grade prostatectomy | Gleason grade biopsy | pN stage | R status | TFAP2D Expression | |||
| all cancers | 1 | 10,827 | <.0001* | <.0001* | – | <.0001* | – | <.0001* | <.0001* | 0.2379 |
| 2 | 10,846 | <.0001* | <.0001* | – | <.0001* | – | – | <.0001* | 0.2712 | |
| 3 | 10,692 | <.0001* | – | <.0001* | <.0001* | – | – | – | 0.0496* | |
| 4 | 9204 | <.0001* | – | <.0001* | – | <.0001* | – | – | 0.0007* | |
| ERG-negative cancers | 1 | 4327 | <.0001* | <.0001* | – | <.0001* | – | 0.8751 | <.0001* | 0.4114 |
| 2 | 4334 | <.0001* | <.0001* | – | <.0001* | – | – | 0.0040* | 0.4285 | |
| 3 | 4298 | <.0001* | – | <.0001* | <.0001* | – | – | – | 0.1722 | |
| 4 | 4228 | <.0001* | – | <.0001* | – | <.0001* | – | – | 0.0007* | |
| ERG- postive cancers | 1 | 3429 | <.0001* | <.0001* | – | <.0001* | – | <.0001* | 0.0001* | 0.61 |
| 2 | 3437 | <.0001* | <.0001* | – | <.0001* | – | – | <.0001* | 0.822 | |
| 3 | 3383 | <.0001* | – | <.0001* | <.0001* | – | – | – | 0.8684 | |
| 4 | 3327 | <.0001* | – | <.0001* | – | <.0001* | – | – | 0.2301 | |
Scenario 1 includes all postoperatively available parameters (pathological tumor (pT) stage, lymph node (pN), surgical margin (R) status, preoperative PSA value and Gleason grade obtained after the morphological evaluation of the entire resected prostate. Scenario 2 excluded the nodal status from analysis. Scenario 3 included preoperative PSA, clinical tumor (cT) stage and Gleason grade obtained on the prostatectomy specimen. In scenario 4, the preoperative Gleason grade obtained on the original biopsy was combined with preoperative PSA, and cT stage (* = significant)